^
    11d
    A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. (PubMed, Cancer Immunol Immunother)
    OH2 exerts antitumor activity in GBM through direct oncolysis and immune microenvironment modulation, highlighting its potential as an immunotherapeutic strategy.
    Journal
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    BS001
    4ms
    Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system. (PubMed, J Immunother Cancer)
    This study identifies a mechanism of OH2-induced PD-L1 expression in PCa and provides a versatile, targeted delivery platform that enables effective intravenous viro-immunotherapy, overcoming key translational barriers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    BS001
    4ms
    OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    BS001 • BS006
    10ms
    OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer (clinicaltrials.gov)
    P2, N=4, Terminated, Binhui Biopharmaceutical Co., Ltd. | N=45 --> 4 | Trial completion date: Dec 2025 --> Oct 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Oct 2024; Strategy adjustment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BS001
    11ms
    OH2 Injection in Melanoma (clinicaltrials.gov)
    P3, N=340, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • BS001
    11ms
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • BS001
    11ms
    OH2 Oncolytic Viral Therapy in Central Nervous System Tumors (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BS001
    11ms
    OH2 Injection in Combination With HX008 for Melanoma. (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Puyouheng (pucotenlimab) • BS001
    over1year
    Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial. (PubMed, J Immunother Cancer)
    Intratumoral injection of oncolytic virus OH2 is well tolerable in patients with sarcoma. Further investigation of OH2 with HX008 in select sarcoma subtypes is warranted.
    P1/2 data • Journal
    |
    CSF2 (Colony stimulating factor 2)
    |
    Puyouheng (pucotenlimab) • BS001
    over1year
    OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    BS001
    over1year
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • BS001
    over1year
    OH2 Oncolytic Viral Therapy in Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    irinotecan • Puyouheng (pucotenlimab) • BS001